Overall survival did not differ between groups ( median 373 months , 95 % CI 323-450 , for gefitinib vs 367 months , 95 % CI 297-437 , for placebo ; hazard ratio [ HR ] 090 , 95 % CI 074-109 , p = 029 ) .